Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ReShape Lifesciences Inc. - SIC # 3840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
RSLS
Nasdaq
3840
www.reshapelifesciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ReShape Lifesciences Inc.
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
- Feb 3rd, 2025 1:31 pm
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
- Jan 13th, 2025 1:31 pm
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
- Nov 14th, 2024 9:05 pm
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
- Nov 12th, 2024 9:05 pm
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
- Nov 12th, 2024 1:31 pm
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology
- Nov 11th, 2024 1:31 pm
Upcoming Stock Splits This Week (September 23 to September 27) – Stay Invested
- Sep 23rd, 2024 1:48 pm
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
- Sep 19th, 2024 12:31 pm
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
- Aug 14th, 2024 8:05 pm
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
- Aug 13th, 2024 12:31 pm
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
- Jul 9th, 2024 4:13 pm
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
- Jul 9th, 2024 12:31 pm
Reshape Lifesciences Inc (RSLS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
- May 16th, 2024 7:07 am
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
- May 15th, 2024 8:05 pm
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
- May 14th, 2024 12:31 pm
ReShape Lifesciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
- Apr 3rd, 2024 11:25 am
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- Apr 1st, 2024 8:05 pm
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
- Mar 28th, 2024 12:31 pm
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
- Mar 4th, 2024 1:31 pm
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
- Feb 22nd, 2024 1:31 pm
Scroll